Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
18.4.2023 11:00:00 EEST | Business Wire | Press release
Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005217/en/
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health (Photo: Business Wire)
BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals A/S (Ferring) have expanded their collaboration with the objective to accelerate world-class life science innovation within women’s health. New activities will include supporting BII to source, and potentially fund and incubate early-stage start-ups and projects within the field of reproductive medicine.
“The new strategic collaboration, highlights Ferring’s continued commitment to invest in early-stage innovation in this area, and we look forward to strengthening our collaboration with BII to accelerate new solutions for patients,” says Armin Metzger, Executive Vice President and Chief Science Officer at Ferring.
The strategic collaboration builds on Ferring’s engagement with BII’s Women’s Health Initiative through Ferring’s membership on the BII Women’s Health Innovation Panel. Women’s health is underserved as only 1% of global healthcare research funding is invested in female-specific conditions beyond oncology.1 The collaboration aims to bridge the gap by supporting early-stage innovation and will leverage BII’s proven expertise in translational science incubation, together with Ferring’s expertise in early-stage development and reproductive medicine.
“Combining BII’s already proven incubation expertise with the industrial expertise and deep insights that Ferring has within women’s health forms a very strong basis for supporting and accelerating our mission of getting more solutions on the market that address the high unmet needs of 50% of the world’s population. We are pleased to collaborate even closer with Ferring to make it happen,” says Trine Bartholdy, Chief Innovation Officer at the BioInnovation Institute.
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, Facebook, Twitter and YouTube.
The BioInnovation Institute Foundation:
At BioInnovation Institute (BII), we accelerate world-class life science start-up innovation for the benefit of people and society. As a non-profit institute, BII operates the company creation programs, Bio Studio, Venture Lab and Venture House, to support life science start-ups with knowledge, network, infrastructure and funding of up to EUR 3 million per project and EUR 1,8 million per start-up. With our expertise, network, funding, and infrastructure, we empower start-ups to succeed and believe in the transformative power of life science innovation. Read more on www.bioinnovationinstitute.com.
1 McKinsey & Company. Unlocking opportunities in women’s healthcare. 2022. Available at: https://www.mckinsey.com/industries/healthcare/our-insights/unlocking-opportunities-in-womens-healthcare [Last accessed April 2023]
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005217/en/
Contact information
For more information, please contact:
Ferring Pharmaceuticals
Björn Lindström
Director, Corporate Communications & Public Affairs
+45 28 78 78 62
Bjoern.lindstroem@ferring.com
BioInnovation Institute
Casper Linnemann
Head of Communication
+45 4172 7994
cli@bii.dk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 10:33:00 EEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 10:00:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evotec is further streamlining these processes through one unified, easy-to-use platform that supports consistency, transpar
Freedom Holding Corp. Works With Ant International’s Antom to Simplify Online Shopping From China for Kazakhstan Consumers23.7.2026 08:30:00 EEST | Press release
On July 16, 2026, during a meeting between Timur Turlov, CEO of Freedom Holding Corp., and representatives of the global fintech market, the bank signed Memoranda of Understanding with Antom, a leading merchant payment and digitisation services provider under Ant International. The primary goal of this partnership is to develop innovative solutions to facilitate cross-border payments for consumers in Kazakhstan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722367119/en/ From left to right: Timur Turlov, CEO of Freedom Holding Corp., Leiming Chen, Senior Vice President and Chief Sustainability Officer of Ant International Antom will promote Freedom Bank SuperApp as a supported payment option on China’s leading e-commerce platforms. This move aims to create a seamless cross-border online shopping experience, allowing consumers in Kazakhstan to shop for Chinese goods and global brands using their preferred local payment me
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year23.7.2026 08:00:00 EEST | Press release
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix. Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology. Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ramp-up with approvals in 33 International ma
ATOZ Services Announces Strategic Growth Investment from Bregal Sagemount23.7.2026 07:30:00 EEST | Press release
ATOZ Services (The “Company”), an independent Luxembourg-based fund services platform, today announced that the Company will accelerate its strategic move to continue its international expansion and acquisition-based strategy through a growth investment from Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm. Sagemount has entered into a partnership with ATOZ Group and ICG that will see Sagemount become the majority shareholder of the Company, while ATOZ Group and ICG retain a minority stake, subject to regulatory approval and other customary procedures. The investment will support the Company’s continued development as an international fund services platform. Founded in 2018 as part of the ATOZ Group, ATOZ Services provides fund-linked special purpose vehicle (“SPV”) services, fund administration, and fund governance, risk and compliance services. The Company has built long-standing relationships with leading alternative investment managers through deep techn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom